Q-omics provides the consensus-scored C18orf15 profile across patient tissues and cancer cell-line models. C18orf15 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C18orf15 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, C18orf15 RNA expression shows 11,079 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where C18orf15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C18orf15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C18orf15 survival associations across molecular data types. C18orf15 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C18orf15 RNA expression–survival associations across cancer types. High C18orf15 expression shows unfavorable associations in ACC, MESO, KIRC, LUSC and KICH, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C18orf15 RNA expression.
This table summarizes C18orf15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C18orf15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C18orf15 shows lower tumor expression in UCEC and KICH and higher tumor expression in HNSC, STAD, KIRC and LIHC. The HNSC box plot shows higher C18orf15 RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .004).
This table shows molecular features associated with C18orf15 in patient tissues and cancer cell lines. In patient samples, C18orf15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
